These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7480380)

  • 41. Extrapyramidal symptoms and neuropsychological deficits in schizophrenia.
    Palmer BW; Heaton RK; Jeste DV
    Biol Psychiatry; 1999 Mar; 45(6):791-4. PubMed ID: 10188011
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia.
    Abuzzahab FS; Zimmerman RL
    J Clin Psychiatry; 1982 Mar; 43(3):105-10. PubMed ID: 7037757
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting cognition in schizophrenia research: from etiology to treatment.
    Goldberg TE; Gomar JJ
    Am J Psychiatry; 2009 Jun; 166(6):631-4. PubMed ID: 19487396
    [No Abstract]   [Full Text] [Related]  

  • 44. Double blind comparison of thiothixene and trifluoperazine in acute schizophrenia.
    Denber HC; Turns D
    Psychosomatics; 1972; 13(2):100-4. PubMed ID: 4604343
    [No Abstract]   [Full Text] [Related]  

  • 45. Context-processing deficits in schizophrenia: diagnostic specificity, 4-week course, and relationships to clinical symptoms.
    Barch DM; Carter CS; MacDonald AW; Braver TS; Cohen JD
    J Abnorm Psychol; 2003 Feb; 112(1):132-43. PubMed ID: 12653421
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of efficacy of zotepine and thiothixene in schizophrenia in a double-blind study.
    Sarai K; Okada M
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):38-46. PubMed ID: 2883680
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dissociating medication effects from learning and practice effects in a neurocognitive study of schizophrenia: Olanzapine versus haloperidol.
    Boulay LJ; Labelle A; Bourget D; Robertson S; Habib R; Tessier P; Tombaugh T; Milin R
    Cogn Neuropsychiatry; 2007 Jul; 12(4):322-38. PubMed ID: 17558641
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neurologic side effects in neuroleptic-naïve patients treated with haloperidol or risperidone.
    Meibach RC
    Neurology; 2000 Oct; 55(7):1069. PubMed ID: 11061283
    [No Abstract]   [Full Text] [Related]  

  • 49. Recent and remote memory dissociation: medication effects and hippocampal function in schizophrenia.
    Gilbertson MW; van Kammen DP
    Biol Psychiatry; 1997 Oct; 42(7):585-95. PubMed ID: 9376455
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Normalization of impaired cognitive functions failed to improve clinical symptomatology in a schizophrenic patient.
    Holzer L; Halfon O
    Eur Psychiatry; 2004 Sep; 19(6):384-6. PubMed ID: 15363482
    [No Abstract]   [Full Text] [Related]  

  • 51. Attentional dysfunctions in neuroleptic-naive and neuroleptic-withdrawn schizophrenic patients and their siblings.
    Finkelstein JR; Cannon TD; Gur RE; Gur RC; Moberg P
    J Abnorm Psychol; 1997 May; 106(2):203-12. PubMed ID: 9131840
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of neuroleptic withdrawal on plasma prolactin: a possible marker of receptor adaptation.
    Kirkpatrick B; Buchanan RW; Maeda K; Carpenter WT; Jauch D; Tamminga CA
    Biol Psychiatry; 1989 Jun; 26(2):131-8. PubMed ID: 2567610
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuroleptic therapy following neuroleptic malignant syndrome.
    Pelonero AL; Levenson JL; Silverman JJ
    Psychosomatics; 1985 Dec; 26(12):946-7. PubMed ID: 4089133
    [No Abstract]   [Full Text] [Related]  

  • 54. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia.
    Minzenberg MJ; Poole JH; Benton C; Vinogradov S
    Am J Psychiatry; 2004 Jan; 161(1):116-24. PubMed ID: 14702259
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neuroleptic-induced reductions in serum dopamine-beta-hydroxylase in schizophrenia.
    Goodnick PJ; Tong C; Duncavage MB; Meltzer HY
    Biol Psychiatry; 1983 Dec; 18(12):1485-8. PubMed ID: 6140962
    [No Abstract]   [Full Text] [Related]  

  • 56. Cognitive neuropsychological functioning in New Zealand Māori diagnosed with schizophrenia.
    Kake TR; Garrett N; Te Aonui M
    Aust N Z J Psychiatry; 2016 Jun; 50(6):566-76. PubMed ID: 26494850
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reduction of functional disability with atypical antipsychotic treatment: a randomized long term comparison of ziprasidone and haloperidol.
    Harvey PD; Pappadopulos E; Lombardo I; Kremer CM
    Schizophr Res; 2009 Nov; 115(1):24-9. PubMed ID: 19189878
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Selegiline for neuroleptic-induced parkinsonism.
    Gewirtz GR; Sharif Z; Cadet JL; Sarti P; Gorman JM
    Pharmacopsychiatry; 1993 Jul; 26(4):128-9. PubMed ID: 7901857
    [No Abstract]   [Full Text] [Related]  

  • 59. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
    Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
    JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The clinical effects of intramuscular thiothixene and trifluoperazine in chronic schizophrenia: a comparative study.
    Holden JM; Itil TM; Gannon PJ; Keskiner A
    Curr Ther Res Clin Exp; 1971 May; 13(5):298-310. PubMed ID: 4998393
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.